The risks and benefits of providing HIV services during the COVID-19 pandemic

The COVID-19 pandemic has caused widespread disruptions including to health services. In the early response to the pandemic many countries restricted population movements and some health services were suspended or limited. In late 2020 and early 2021 some countries re-imposed restrictions. Health au...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2021-12, Vol.16 (12), p.e0260820-e0260820
Hauptverfasser: Stover, John, Kelly, Sherrie L, Mudimu, Edinah, Green, Dylan, Smith, Tyler, Taramusi, Isaac, Bansi-Matharu, Loveleen, Martin-Hughes, Rowan, Phillips, Andrew N, Bershteyn, Anna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e0260820
container_issue 12
container_start_page e0260820
container_title PloS one
container_volume 16
creator Stover, John
Kelly, Sherrie L
Mudimu, Edinah
Green, Dylan
Smith, Tyler
Taramusi, Isaac
Bansi-Matharu, Loveleen
Martin-Hughes, Rowan
Phillips, Andrew N
Bershteyn, Anna
description The COVID-19 pandemic has caused widespread disruptions including to health services. In the early response to the pandemic many countries restricted population movements and some health services were suspended or limited. In late 2020 and early 2021 some countries re-imposed restrictions. Health authorities need to balance the potential harms of additional SARS-CoV-2 transmission due to contacts associated with health services against the benefits of those services, including fewer new HIV infections and deaths. This paper examines these trade-offs for select HIV services. We used four HIV simulation models (Goals, HIV Synthesis, Optima HIV and EMOD) to estimate the benefits of continuing HIV services in terms of fewer new HIV infections and deaths. We used three COVID-19 transmission models (Covasim, Cooper/Smith and a simple contact model) to estimate the additional deaths due to SARS-CoV-2 transmission among health workers and clients. We examined four HIV services: voluntary medical male circumcision, HIV diagnostic testing, viral load testing and programs to prevent mother-to-child transmission. We compared COVID-19 deaths in 2020 and 2021 with HIV deaths occurring now and over the next 50 years discounted to present value. The models were applied to countries with a range of HIV and COVID-19 epidemics. Maintaining these HIV services could lead to additional COVID-19 deaths of 0.002 to 0.15 per 10,000 clients. HIV-related deaths averted are estimated to be much larger, 19-146 discounted deaths per 10,000 clients. While there is some additional short-term risk of SARS-CoV-2 transmission associated with providing HIV services, the risk of additional COVID-19 deaths is at least 100 times less than the HIV deaths averted by those services. Ministries of Health need to take into account many factors in deciding when and how to offer essential health services during the COVID-19 pandemic. This work shows that the benefits of continuing key HIV services are far larger than the risks of additional SARS-CoV-2 transmission.
doi_str_mv 10.1371/journal.pone.0260820
format Article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2613261041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A687760035</galeid><doaj_id>oai_doaj_org_article_47ecafebb8af45bcbdeb617a7274fff8</doaj_id><sourcerecordid>A687760035</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-185db76da2972cb5e36f7761052e36e06413833c842ef47ada208aacd5905a073</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhiMEYqPwDxBEQkJw0eKPxI5vkKbysUpDlWD01nKc49YljTs7qeDf43TZ1KBdIMuydfy8r-1zTpK8xGiGKccftq7zjapne9fADBGGCoIeJedYUDJlBNHHJ_uz5FkIW4RyWjD2NDmjmchwwdl58u16A6m34VdIVVOlJTRgbBtSZ9K9dwdb2WadXi5WaQB_sBpCWnW-j7VRN1-uFp-mWKT7qIWd1c-TJ0bVAV4M6yT5-eXz9fxyerX8uphfXE01E6Sd4iKvSs4qRQQnusyBMsM5wygncQuIZZgWlOoiI2AyriKICqV0lQuUK8TpJHl967uvXZBDJoIkDNM4UZRPksUtUTm1lXtvd8r_kU5ZeQw4v5bKt1bXIDMOWhkoy0KZLC91WUHJMFec8MwYU0Svj8NtXbmDSkPTelWPTMcnjd3ItTvIggkhuIgG7wYD7246CK3c2aChrlUDrju-OyNE5Hn_7jf_oA__bqDWKn7ANsbFe3VvKi9YEVOJEM0jNXuAiuNYK9dXOsZHgvcjQWRa-N2uVReCXPz4_v_scjVm356wG1B1uwmu7lrrmjAGs1tQexeCB3OfZIxk3_V32ZB918uh66Ps1WmB7kV3bU7_Aon8-u4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2613261041</pqid></control><display><type>article</type><title>The risks and benefits of providing HIV services during the COVID-19 pandemic</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Stover, John ; Kelly, Sherrie L ; Mudimu, Edinah ; Green, Dylan ; Smith, Tyler ; Taramusi, Isaac ; Bansi-Matharu, Loveleen ; Martin-Hughes, Rowan ; Phillips, Andrew N ; Bershteyn, Anna</creator><contributor>Ndeffo Mbah, Martial L.</contributor><creatorcontrib>Stover, John ; Kelly, Sherrie L ; Mudimu, Edinah ; Green, Dylan ; Smith, Tyler ; Taramusi, Isaac ; Bansi-Matharu, Loveleen ; Martin-Hughes, Rowan ; Phillips, Andrew N ; Bershteyn, Anna ; Ndeffo Mbah, Martial L.</creatorcontrib><description>The COVID-19 pandemic has caused widespread disruptions including to health services. In the early response to the pandemic many countries restricted population movements and some health services were suspended or limited. In late 2020 and early 2021 some countries re-imposed restrictions. Health authorities need to balance the potential harms of additional SARS-CoV-2 transmission due to contacts associated with health services against the benefits of those services, including fewer new HIV infections and deaths. This paper examines these trade-offs for select HIV services. We used four HIV simulation models (Goals, HIV Synthesis, Optima HIV and EMOD) to estimate the benefits of continuing HIV services in terms of fewer new HIV infections and deaths. We used three COVID-19 transmission models (Covasim, Cooper/Smith and a simple contact model) to estimate the additional deaths due to SARS-CoV-2 transmission among health workers and clients. We examined four HIV services: voluntary medical male circumcision, HIV diagnostic testing, viral load testing and programs to prevent mother-to-child transmission. We compared COVID-19 deaths in 2020 and 2021 with HIV deaths occurring now and over the next 50 years discounted to present value. The models were applied to countries with a range of HIV and COVID-19 epidemics. Maintaining these HIV services could lead to additional COVID-19 deaths of 0.002 to 0.15 per 10,000 clients. HIV-related deaths averted are estimated to be much larger, 19-146 discounted deaths per 10,000 clients. While there is some additional short-term risk of SARS-CoV-2 transmission associated with providing HIV services, the risk of additional COVID-19 deaths is at least 100 times less than the HIV deaths averted by those services. Ministries of Health need to take into account many factors in deciding when and how to offer essential health services during the COVID-19 pandemic. This work shows that the benefits of continuing key HIV services are far larger than the risks of additional SARS-CoV-2 transmission.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0260820</identifier><identifier>PMID: 34941876</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Behavior modification ; Biology and Life Sciences ; Care and treatment ; Circumcision ; Clients ; Coronaviruses ; Cost-benefit analysis ; COVID-19 ; COVID-19 - complications ; COVID-19 - epidemiology ; COVID-19 - transmission ; Diagnosis ; Diagnostic tests ; Disease prevention ; Disease transmission ; Drug therapy ; Epidemics ; Fatalities ; Health aspects ; Health risks ; Health services ; Health Services - trends ; Health Services Accessibility - trends ; Health Services Administration ; HIV ; HIV infection ; HIV Infections - complications ; HIV Infections - epidemiology ; HIV Infections - therapy ; HIV-1 - pathogenicity ; Human immunodeficiency virus ; Humans ; Infections ; Medical diagnosis ; Medical personnel ; Medical tests ; Medicine and Health Sciences ; Methods ; Modelling ; Models, Theoretical ; Pandemics ; Pandemics - prevention &amp; control ; People and Places ; Population ; Prevention ; Public health ; Risk Assessment - methods ; Risk factors ; SARS-CoV-2 - pathogenicity ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Sex industry ; Simulation ; Transportation services ; Viral diseases</subject><ispartof>PloS one, 2021-12, Vol.16 (12), p.e0260820-e0260820</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Stover et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Stover et al 2021 Stover et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-185db76da2972cb5e36f7761052e36e06413833c842ef47ada208aacd5905a073</citedby><cites>FETCH-LOGICAL-c692t-185db76da2972cb5e36f7761052e36e06413833c842ef47ada208aacd5905a073</cites><orcidid>0000-0002-3724-2412 ; 0000-0002-6232-5586 ; 0000-0001-7236-1989</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699979/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699979/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34941876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ndeffo Mbah, Martial L.</contributor><creatorcontrib>Stover, John</creatorcontrib><creatorcontrib>Kelly, Sherrie L</creatorcontrib><creatorcontrib>Mudimu, Edinah</creatorcontrib><creatorcontrib>Green, Dylan</creatorcontrib><creatorcontrib>Smith, Tyler</creatorcontrib><creatorcontrib>Taramusi, Isaac</creatorcontrib><creatorcontrib>Bansi-Matharu, Loveleen</creatorcontrib><creatorcontrib>Martin-Hughes, Rowan</creatorcontrib><creatorcontrib>Phillips, Andrew N</creatorcontrib><creatorcontrib>Bershteyn, Anna</creatorcontrib><title>The risks and benefits of providing HIV services during the COVID-19 pandemic</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The COVID-19 pandemic has caused widespread disruptions including to health services. In the early response to the pandemic many countries restricted population movements and some health services were suspended or limited. In late 2020 and early 2021 some countries re-imposed restrictions. Health authorities need to balance the potential harms of additional SARS-CoV-2 transmission due to contacts associated with health services against the benefits of those services, including fewer new HIV infections and deaths. This paper examines these trade-offs for select HIV services. We used four HIV simulation models (Goals, HIV Synthesis, Optima HIV and EMOD) to estimate the benefits of continuing HIV services in terms of fewer new HIV infections and deaths. We used three COVID-19 transmission models (Covasim, Cooper/Smith and a simple contact model) to estimate the additional deaths due to SARS-CoV-2 transmission among health workers and clients. We examined four HIV services: voluntary medical male circumcision, HIV diagnostic testing, viral load testing and programs to prevent mother-to-child transmission. We compared COVID-19 deaths in 2020 and 2021 with HIV deaths occurring now and over the next 50 years discounted to present value. The models were applied to countries with a range of HIV and COVID-19 epidemics. Maintaining these HIV services could lead to additional COVID-19 deaths of 0.002 to 0.15 per 10,000 clients. HIV-related deaths averted are estimated to be much larger, 19-146 discounted deaths per 10,000 clients. While there is some additional short-term risk of SARS-CoV-2 transmission associated with providing HIV services, the risk of additional COVID-19 deaths is at least 100 times less than the HIV deaths averted by those services. Ministries of Health need to take into account many factors in deciding when and how to offer essential health services during the COVID-19 pandemic. This work shows that the benefits of continuing key HIV services are far larger than the risks of additional SARS-CoV-2 transmission.</description><subject>Behavior modification</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Circumcision</subject><subject>Clients</subject><subject>Coronaviruses</subject><subject>Cost-benefit analysis</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - transmission</subject><subject>Diagnosis</subject><subject>Diagnostic tests</subject><subject>Disease prevention</subject><subject>Disease transmission</subject><subject>Drug therapy</subject><subject>Epidemics</subject><subject>Fatalities</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Health services</subject><subject>Health Services - trends</subject><subject>Health Services Accessibility - trends</subject><subject>Health Services Administration</subject><subject>HIV</subject><subject>HIV infection</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - therapy</subject><subject>HIV-1 - pathogenicity</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Medical diagnosis</subject><subject>Medical personnel</subject><subject>Medical tests</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Modelling</subject><subject>Models, Theoretical</subject><subject>Pandemics</subject><subject>Pandemics - prevention &amp; control</subject><subject>People and Places</subject><subject>Population</subject><subject>Prevention</subject><subject>Public health</subject><subject>Risk Assessment - methods</subject><subject>Risk factors</subject><subject>SARS-CoV-2 - pathogenicity</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Sex industry</subject><subject>Simulation</subject><subject>Transportation services</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1v0zAUhiMEYqPwDxBEQkJw0eKPxI5vkKbysUpDlWD01nKc49YljTs7qeDf43TZ1KBdIMuydfy8r-1zTpK8xGiGKccftq7zjapne9fADBGGCoIeJedYUDJlBNHHJ_uz5FkIW4RyWjD2NDmjmchwwdl58u16A6m34VdIVVOlJTRgbBtSZ9K9dwdb2WadXi5WaQB_sBpCWnW-j7VRN1-uFp-mWKT7qIWd1c-TJ0bVAV4M6yT5-eXz9fxyerX8uphfXE01E6Sd4iKvSs4qRQQnusyBMsM5wygncQuIZZgWlOoiI2AyriKICqV0lQuUK8TpJHl967uvXZBDJoIkDNM4UZRPksUtUTm1lXtvd8r_kU5ZeQw4v5bKt1bXIDMOWhkoy0KZLC91WUHJMFec8MwYU0Svj8NtXbmDSkPTelWPTMcnjd3ItTvIggkhuIgG7wYD7246CK3c2aChrlUDrju-OyNE5Hn_7jf_oA__bqDWKn7ANsbFe3VvKi9YEVOJEM0jNXuAiuNYK9dXOsZHgvcjQWRa-N2uVReCXPz4_v_scjVm356wG1B1uwmu7lrrmjAGs1tQexeCB3OfZIxk3_V32ZB918uh66Ps1WmB7kV3bU7_Aon8-u4</recordid><startdate>20211223</startdate><enddate>20211223</enddate><creator>Stover, John</creator><creator>Kelly, Sherrie L</creator><creator>Mudimu, Edinah</creator><creator>Green, Dylan</creator><creator>Smith, Tyler</creator><creator>Taramusi, Isaac</creator><creator>Bansi-Matharu, Loveleen</creator><creator>Martin-Hughes, Rowan</creator><creator>Phillips, Andrew N</creator><creator>Bershteyn, Anna</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3724-2412</orcidid><orcidid>https://orcid.org/0000-0002-6232-5586</orcidid><orcidid>https://orcid.org/0000-0001-7236-1989</orcidid></search><sort><creationdate>20211223</creationdate><title>The risks and benefits of providing HIV services during the COVID-19 pandemic</title><author>Stover, John ; Kelly, Sherrie L ; Mudimu, Edinah ; Green, Dylan ; Smith, Tyler ; Taramusi, Isaac ; Bansi-Matharu, Loveleen ; Martin-Hughes, Rowan ; Phillips, Andrew N ; Bershteyn, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-185db76da2972cb5e36f7761052e36e06413833c842ef47ada208aacd5905a073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Behavior modification</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Circumcision</topic><topic>Clients</topic><topic>Coronaviruses</topic><topic>Cost-benefit analysis</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - transmission</topic><topic>Diagnosis</topic><topic>Diagnostic tests</topic><topic>Disease prevention</topic><topic>Disease transmission</topic><topic>Drug therapy</topic><topic>Epidemics</topic><topic>Fatalities</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Health services</topic><topic>Health Services - trends</topic><topic>Health Services Accessibility - trends</topic><topic>Health Services Administration</topic><topic>HIV</topic><topic>HIV infection</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - therapy</topic><topic>HIV-1 - pathogenicity</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Medical diagnosis</topic><topic>Medical personnel</topic><topic>Medical tests</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Modelling</topic><topic>Models, Theoretical</topic><topic>Pandemics</topic><topic>Pandemics - prevention &amp; control</topic><topic>People and Places</topic><topic>Population</topic><topic>Prevention</topic><topic>Public health</topic><topic>Risk Assessment - methods</topic><topic>Risk factors</topic><topic>SARS-CoV-2 - pathogenicity</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Sex industry</topic><topic>Simulation</topic><topic>Transportation services</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stover, John</creatorcontrib><creatorcontrib>Kelly, Sherrie L</creatorcontrib><creatorcontrib>Mudimu, Edinah</creatorcontrib><creatorcontrib>Green, Dylan</creatorcontrib><creatorcontrib>Smith, Tyler</creatorcontrib><creatorcontrib>Taramusi, Isaac</creatorcontrib><creatorcontrib>Bansi-Matharu, Loveleen</creatorcontrib><creatorcontrib>Martin-Hughes, Rowan</creatorcontrib><creatorcontrib>Phillips, Andrew N</creatorcontrib><creatorcontrib>Bershteyn, Anna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints in Context (Gale)</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stover, John</au><au>Kelly, Sherrie L</au><au>Mudimu, Edinah</au><au>Green, Dylan</au><au>Smith, Tyler</au><au>Taramusi, Isaac</au><au>Bansi-Matharu, Loveleen</au><au>Martin-Hughes, Rowan</au><au>Phillips, Andrew N</au><au>Bershteyn, Anna</au><au>Ndeffo Mbah, Martial L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The risks and benefits of providing HIV services during the COVID-19 pandemic</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-12-23</date><risdate>2021</risdate><volume>16</volume><issue>12</issue><spage>e0260820</spage><epage>e0260820</epage><pages>e0260820-e0260820</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The COVID-19 pandemic has caused widespread disruptions including to health services. In the early response to the pandemic many countries restricted population movements and some health services were suspended or limited. In late 2020 and early 2021 some countries re-imposed restrictions. Health authorities need to balance the potential harms of additional SARS-CoV-2 transmission due to contacts associated with health services against the benefits of those services, including fewer new HIV infections and deaths. This paper examines these trade-offs for select HIV services. We used four HIV simulation models (Goals, HIV Synthesis, Optima HIV and EMOD) to estimate the benefits of continuing HIV services in terms of fewer new HIV infections and deaths. We used three COVID-19 transmission models (Covasim, Cooper/Smith and a simple contact model) to estimate the additional deaths due to SARS-CoV-2 transmission among health workers and clients. We examined four HIV services: voluntary medical male circumcision, HIV diagnostic testing, viral load testing and programs to prevent mother-to-child transmission. We compared COVID-19 deaths in 2020 and 2021 with HIV deaths occurring now and over the next 50 years discounted to present value. The models were applied to countries with a range of HIV and COVID-19 epidemics. Maintaining these HIV services could lead to additional COVID-19 deaths of 0.002 to 0.15 per 10,000 clients. HIV-related deaths averted are estimated to be much larger, 19-146 discounted deaths per 10,000 clients. While there is some additional short-term risk of SARS-CoV-2 transmission associated with providing HIV services, the risk of additional COVID-19 deaths is at least 100 times less than the HIV deaths averted by those services. Ministries of Health need to take into account many factors in deciding when and how to offer essential health services during the COVID-19 pandemic. This work shows that the benefits of continuing key HIV services are far larger than the risks of additional SARS-CoV-2 transmission.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34941876</pmid><doi>10.1371/journal.pone.0260820</doi><tpages>e0260820</tpages><orcidid>https://orcid.org/0000-0002-3724-2412</orcidid><orcidid>https://orcid.org/0000-0002-6232-5586</orcidid><orcidid>https://orcid.org/0000-0001-7236-1989</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2021-12, Vol.16 (12), p.e0260820-e0260820
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2613261041
source MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Behavior modification
Biology and Life Sciences
Care and treatment
Circumcision
Clients
Coronaviruses
Cost-benefit analysis
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 - transmission
Diagnosis
Diagnostic tests
Disease prevention
Disease transmission
Drug therapy
Epidemics
Fatalities
Health aspects
Health risks
Health services
Health Services - trends
Health Services Accessibility - trends
Health Services Administration
HIV
HIV infection
HIV Infections - complications
HIV Infections - epidemiology
HIV Infections - therapy
HIV-1 - pathogenicity
Human immunodeficiency virus
Humans
Infections
Medical diagnosis
Medical personnel
Medical tests
Medicine and Health Sciences
Methods
Modelling
Models, Theoretical
Pandemics
Pandemics - prevention & control
People and Places
Population
Prevention
Public health
Risk Assessment - methods
Risk factors
SARS-CoV-2 - pathogenicity
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Sex industry
Simulation
Transportation services
Viral diseases
title The risks and benefits of providing HIV services during the COVID-19 pandemic
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T01%3A50%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20risks%20and%20benefits%20of%20providing%20HIV%20services%20during%20the%20COVID-19%20pandemic&rft.jtitle=PloS%20one&rft.au=Stover,%20John&rft.date=2021-12-23&rft.volume=16&rft.issue=12&rft.spage=e0260820&rft.epage=e0260820&rft.pages=e0260820-e0260820&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0260820&rft_dat=%3Cgale_plos_%3EA687760035%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2613261041&rft_id=info:pmid/34941876&rft_galeid=A687760035&rft_doaj_id=oai_doaj_org_article_47ecafebb8af45bcbdeb617a7274fff8&rfr_iscdi=true